Critical toxic species behind Parkinson's disease is glimpsed at work for the first time

December 14, 2017, St John's College, University of Cambridge
The study found that a structural core within a toxic tangle of alpha-synuclein protein molecules allows it to insert itself into the wall of a neuron. Credit: Alfonso De Simone

Researchers have glimpsed how the toxic protein clusters that are associated with Parkinson's Disease disrupt the membranes of healthy brain cells, creating defects in the cell walls and eventually causing a series of events that induce neuronal death.

The study examined what are known as toxic oligomers, clusters of protein molecules that emerge when individual proteins misfold and clump together. In the case of Parkinson's Disease, the protein involved is called , which when it is functioning normally plays an important part in signalling in the brain.

The formation and spread of these clusters is thought to be a key component of the underlying molecular mechanisms of this progressive illness. Understanding how they enter and damage cells presents an opportunity to develop new and more effective treatments. But until now, studying how they damage brain cells has been extremely difficult as they are typically unstable. Shortly after forming they either fall apart, or assemble into larger structures that are less damaging to individual cells.

In the new study, academics were able to stabilise oligomers long enough to examine how they damage brain cell walls in unprecedented detail. They identified a specific feature of the oligomer which allows it to latch on to the , and a "structural core", which then breaks through.

The research was carried out by an international team of scientists from the UK, Italy and Spain, led by Professor Christopher Dobson, at the University of Cambridge, and Dr Alfonso De Simone, from Imperial College London.

"It is a common property of oligomers that they can damage brain cells once they bind to the surface," De Simone explained. "It is a bit like if you put a piece of extremely hot metal on to a plastic surface. In a fairly short space of time it will burn a hole through the plastic. The oligomer does something similar when it comes into contact with the cell membrane, and this disrupts the integrity of the membrane, which is the key step in the mechanisms leading to the death of the neuron."

Dr Giuliana Fusco, a postdoctoral researcher at St John's College, Cambridge who carried out much of the experimental work for the study while working towards her PhD, said: "Just having this information doesn't mean that we can now go and make a drug, but obviously if we can understand why these clumps of proteins behave the way they do, we can make faster scientific progress towards treating Parkinson's Disease. It means we can take a more rational approach to drug discovery."

Toxic oligomers form at an early stage in the series of events that lead to Parkinson's Disease, which are believed to begin when alpha synuclein proteins malfunction and begin to stick together. Their emergence is lethal to neuronal function in this context. Once the oligomers have formed, they disperse, and allow the initial toxicity to spread to other cells.

In the study, researchers examined samples in the lab of both toxic and non-toxic forms of oligomeric alpha synuclein oligomers using solid state nuclear magnetic resonance spectroscopy (SSNMR). Recent developments in this technology enabled them to study the oligomers in a level of detail that was not previously possible. The research team characterised different features of the structures, and then studied how these various properties influenced their interactions with sample taken from rats, as well as additional taken from human brain tumours.

The study's results could, in particular, inform the identification of molecules that can attack these damaging toxins and hence limit their impact. In October this year, the University of Cambridge launched a new Centre for Misfolding Diseases, based in the Department of Chemistry, and geared towards developing therapeutic strategies for a range of conditions including Parkinson's Disease. Much of its work will build on studies which, like this one, enhance scientific understanding of the fundamental processes that underlie neurodegeneration. From this, molecular "candidates" that might be used in future drugs can be both identified and, if necessary, optimised to target disease.

Professor Dobson, who is both Master of St John's College, Cambridge, and a Director of the Centre for Misfolding Diseases, said: "One of the really exciting things about this work is that not only has it been possible to define the structure of the critical pathogenic species in a neurodegenerative disorder, but we have also managed to propose a mechanism for its toxicity, providing vital clues for pursuing rational therapeutic strategies.."

The report, Structural basis of membrane disruption and cellular toxicity by a-synuclein oligomers, is published in the journal Science.

Explore further: Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

More information: "Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers" Science (2017). science.sciencemag.org/cgi/doi … 1126/science.aan6160

Related Stories

Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

July 3, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.

Tug of war between Parkinson's protein and growth factor

September 18, 2017
Alpha-synuclein, a sticky and sometimes toxic protein involved in Parkinson's disease (PD), blocks signals from an important brain growth factor, Emory researchers have discovered.

Imaging technique measures toxicity of Alzheimer's and Parkinson's proteins

November 23, 2016
Researchers have developed a new imaging technique that makes it possible to study why proteins associated with Alzheimer's and Parkinson's diseases may go from harmless to toxic. The technique uses a technology called multi-dimensional ...

Parkinson's disease protein plays vital 'marshalling' role in healthy brains

September 19, 2016
Researchers have uncovered the normal function of a protein associated with Parkinson's disease, giving clues about what happens when it malfunctions.

New antibodies target protein structures common to several neurological diseases

August 29, 2017
A new kind of antibody targets a feature shared by proteins thought to cause the most damage in Alzheimer's disease, Parkinson's disease, and related conditions, creating potential for a unified treatment approach.

Researchers identify when Parkinson's proteins become toxic to brain cells

March 14, 2016
Researchers have used a non-invasive method of observing how the process leading to Parkinson's disease takes place at the nanoscale, and identified the point in the process at which proteins in the brain become toxic, eventually ...

Recommended for you

Study identifies chaperone protein implicated in Parkinson's disease

August 13, 2018
Reduced levels of a chaperone protein might have implications for the development and progression of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia, according to new research from investigators ...

Function of gene mutations linked to neurological diseases identified

August 10, 2018
Several gene mutations have been linked to Parkinson's disease, but exactly how and where some of them cause their damage has been unclear. A new Yale study, published in the Journal of Cell Biology, shows that one of the ...

Biomarkers link fatigue in cancer, Parkinson's

August 9, 2018
Biological markers responsible for extreme exhaustion in patients with cancer have now been linked to fatigue in those with Parkinson's disease, according to new research from Rice University.

Researchers examining Parkinson's resilience

August 2, 2018
Diseases have a spectrum of risk, even those partially embedded in genes such as Parkinson's disease.

Japan human trial tests iPS cell treatment for Parkinson's

July 30, 2018
Japanese researchers on Monday announced the first human trial using a kind of stem cell to treat Parkinson's disease, building on earlier animal trials.

New ceria nanoparticles attack Parkinson's disease from three fronts

July 27, 2018
Researchers at the Center for Nanoparticle Research, within the Institute for Basic Science (IBS, South Korea), have developed a set of nanoparticles for Parkinson's disease treatment. Tested in mice and published in Angewandte ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.